Abbvie Inc. Common Stock (ABBV) 58.05 $ABBV
2 Small Biotech Stocks Dreaming Big in Hepatitis C
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - 11 mins ago
Hepatitis C treatment has progressed by leaps and bounds in the past few years, and appears to be accelerating even more quickly now. Cure rates have increased, treatment times are plummeting, and side effects are falling away. Is now the time to...
JNJ: 99.62 (+1.18), VRTX: 113.66 (+4.03), ISIS: 63.86 (-0.43), ALNY: 95.54 (+1.67), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), SHPG: 239.82 (+6.11), MRK: 58.81 (-0.07), CVS: 102.63 (-0.37), ABBV: 58.05 (+1.00), RGLS: 16.85 (-0.13)
Achillion Pharmaceuticals: High Marketing Potential With Long-Term Prospects
Steven Giardino - at Seeking Alpha - 37 mins ago
GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00)
1 Number Shows Why Gilead Sciences, Inc. Shareholders Should Be Thrilled Right Now
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 14, 7:04AM CST
Source: Gilead Sciences Thanks to launching the billion dollar blockbuster hepatitis C drugs Sovaldi and Harvoni, Gilead Sciences posted some pretty eye-popping numbers in 2014. In fact, these numbers are so impressive that I'm going to reel...
ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), ABBV: 58.05 (+1.00)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)
3 Health Care Stocks On The Rise
at The Street - Fri Feb 13, 11:04AM CST
TheStreet highlights 3 stocks pushing the health care sector higher today.
ABT: 46.09 (+0.87), ALXN: 182.29 (+6.02), ABBV: 58.05 (+1.00)
FDA accepts Pfizer's NDA for abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 10:22AM CST
MNK: 115.01 (+2.51), LCI: 57.78 (-0.91), ACT: 285.37 (+3.71), ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58), ALKS: 71.40 (-1.89)
Shire Misses on Q4 Earnings, Revenues Beat; Shares Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:54AM CST
Shire plc (SHPG) reported fourth-quarter 2014 earnings (excluding special items and amortization) of $2.63 per American Depositary Share (ADS), missed the Zacks Consensus Estimate of $2.66.
SHPG: 239.82 (+6.11), SCMP: 15.32 (+0.04), NPSP: 45.88 (+0.03), ABBV: 58.05 (+1.00)
AbbVie Seeks Japanese Approval for HCV Cocktail Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 12:30PM CST
AbbVie (ABBV) filed a new drug application with the Japanese Ministry of Health, Labour and Welfare for its experimental, all-oral, ribavirin and interferon free hepatitis C virus treatment.
ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), ABBV: 58.05 (+1.00)
A Detailed Look At Why ANI Pharmaceuticals Should Outperform Short Term And Long Term.
Just the Facts Maam - at Seeking Alpha - Thu Feb 12, 10:34AM CST
ANIP: 62.69 (-0.43), ABBV: 58.05 (+1.00)
AbbVie files NDA in Japan for 12-week once-daily HCV combo med
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 10:25AM CST
GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00), ENTA: 33.30 (-0.44)
Shire Moves Up On NPS Potential; Q4 Earnings Miss
at Investor's Business Daily - Thu Feb 12, 9:45AM CST
Shares of Shire (SHPG) moved higher early Thursday as the Irish drugmaker's better-than-expected quarterly revenue and upbeat 2015 outlook offset an earnings miss. Reporting before the open, Shire logged fourth-quarter earnings of $2.63 per American...
AGN: 229.49 (+1.87), VRX: 167.00 (-0.50), SHPG: 239.82 (+6.11), SLXP: 152.35 (+3.17), NPSP: 45.88 (+0.03), ABBV: 58.05 (+1.00)
Acadia Pharmaceuticals Could Be The Most Sought After Company Of 2015
Investing Healthcare - at Seeking Alpha - Thu Feb 12, 8:40AM CST
ACAD: 34.21 (+0.37), AZN: 69.96 (+0.20), PDP: 42.52 (+0.28), ABBV: 58.05 (+1.00)
AbbVie Submits New Drug Application in Japan for its Investigational, All-Oral, Treatment for Chronic Hepatitis C
PR Newswire Europe - Wed Feb 11, 9:15PM CST
- Submission based on Phase 3 GIFT-I study in patients with genotype 1b chronic hepatitis C virus infection
ABBV: 58.05 (+1.00)
Axial Spondyloarthritis - Global Clinical Trials Review 2015
M2 - Wed Feb 11, 2:31PM CST
Research and Markets (http://www.researchandmarkets.com/research/lzmwwt/axial) has announced the addition of the "Axial Spondyloarthritis Global Clinical Trials Review, H1, 2015" report to their offering. This report provides elemental information and data relating to the clinical trials on Axial Spondyloarthritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Axial Spondyloarthritis. Scope: - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Pfizer Inc. - AbbVie Inc. - UCB Biosciences Inc. - Merck & Co., Inc. - UCB Biosciences GmbH Clinical Trial Overview of Top Institutes / Government - Glostrup University Hospital - Ghent University Hospital - Charite - Universitatsmedizin Berlin - Sociedad Espanola de Farmacologia Clinica - The First Affiliated Hospital of Zhengzhou University - Diakonhjemmet Hospital - Rheumatism Foundation Hospital - Tuen Mun Hospital - University hospital of North Norway - University of Zurich For more information visit http://www.researchandmarkets.com/research/lzmwwt/axial
PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00)
Comments On Gilead's Quarter And The Road Ahead
DoctoRx - at Seeking Alpha - Wed Feb 11, 11:57AM CST
JNJ: 99.62 (+1.18), PCYC: 163.28 (+0.23), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00)
6 Ways Rite Aid's Acquisition Of EnvisionRx Will Take Its Stock Higher
Brian Nichols - at Seeking Alpha - Wed Feb 11, 11:15AM CST
GILD: 101.90 (+1.10), CVS: 102.63 (-0.37), ABBV: 58.05 (+1.00), RAD: 8.34 (+0.25)
Biotech Stock Roundup: Achillion Impresses with HCV Data, Regeneron 4Q Results Top Estimates - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 11, 10:47AM CST
The hepatitis C virus (HCV) market remains in focus with Achillion (ACHN) presenting encouraging data.
GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), ABBV: 58.05 (+1.00), ALKS: 71.40 (-1.89), REGN: 402.40 (+0.66), XNPT: 6.69 (-0.21), CELG: 115.88 (+0.16)
Congratulations Covidien: You Escaped In Time
Chris DeMuth Jr. - Seeking Alpha - Wed Feb 11, 8:19AM CST
Originally published on February 4, 2015 The Shakedown In 2014, Obama vowed to punish tax inverting companies by any means necessary - inside and outside of legislation. He took scalps including Shire (NASDAQ: SHPG ) and Walgreens (NASDAQ: WBA...
VRX: 167.00 (-0.50), WBA: 78.73 (-1.23), MDT: 75.26 (+0.33), COV: 106.71 (-1.36), SHPG: 239.82 (+6.11), SLXP: 152.35 (+3.17), NPSP: 45.88 (+0.03), ABBV: 58.05 (+1.00)
Achillion: Hep C Drug Discounting May Hurt Our Market Value, Stock Price
at The Street - Wed Feb 11, 8:04AM CST
Achillion Pharmaceuticals announced a 10 million-share stock offering Tuesday night.
ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), CVS: 102.63 (-0.37), ABBV: 58.05 (+1.00)
2 Small Biotech Stocks Dreaming Big in Hepatitis C
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - 11 mins ago
Hepatitis C treatment has progressed by leaps and bounds in the past few years, and appears to be accelerating even more quickly now. Cure rates have increased, treatment times are plummeting, and side effects are falling away. Is now the time to...
JNJ: 99.62 (+1.18), VRTX: 113.66 (+4.03), ISIS: 63.86 (-0.43), ALNY: 95.54 (+1.67), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), SHPG: 239.82 (+6.11), MRK: 58.81 (-0.07), CVS: 102.63 (-0.37), ABBV: 58.05 (+1.00), RGLS: 16.85 (-0.13)
Achillion Pharmaceuticals: High Marketing Potential With Long-Term Prospects
Steven Giardino - at Seeking Alpha - 37 mins ago
GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00)
1 Number Shows Why Gilead Sciences, Inc. Shareholders Should Be Thrilled Right Now
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 14, 7:04AM CST
Source: Gilead Sciences Thanks to launching the billion dollar blockbuster hepatitis C drugs Sovaldi and Harvoni, Gilead Sciences posted some pretty eye-popping numbers in 2014. In fact, these numbers are so impressive that I'm going to reel...
ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), ABBV: 58.05 (+1.00)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)
3 Health Care Stocks On The Rise
at The Street - Fri Feb 13, 11:04AM CST
TheStreet highlights 3 stocks pushing the health care sector higher today.
ABT: 46.09 (+0.87), ALXN: 182.29 (+6.02), ABBV: 58.05 (+1.00)
FDA accepts Pfizer's NDA for abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 10:22AM CST
MNK: 115.01 (+2.51), LCI: 57.78 (-0.91), ACT: 285.37 (+3.71), ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58), ALKS: 71.40 (-1.89)
Shire Misses on Q4 Earnings, Revenues Beat; Shares Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:54AM CST
Shire plc (SHPG) reported fourth-quarter 2014 earnings (excluding special items and amortization) of $2.63 per American Depositary Share (ADS), missed the Zacks Consensus Estimate of $2.66.
SHPG: 239.82 (+6.11), SCMP: 15.32 (+0.04), NPSP: 45.88 (+0.03), ABBV: 58.05 (+1.00)
AbbVie Seeks Japanese Approval for HCV Cocktail Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 12:30PM CST
AbbVie (ABBV) filed a new drug application with the Japanese Ministry of Health, Labour and Welfare for its experimental, all-oral, ribavirin and interferon free hepatitis C virus treatment.
ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), ABBV: 58.05 (+1.00)
A Detailed Look At Why ANI Pharmaceuticals Should Outperform Short Term And Long Term.
Just the Facts Maam - at Seeking Alpha - Thu Feb 12, 10:34AM CST
ANIP: 62.69 (-0.43), ABBV: 58.05 (+1.00)
AbbVie files NDA in Japan for 12-week once-daily HCV combo med
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 10:25AM CST
GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00), ENTA: 33.30 (-0.44)
Shire Moves Up On NPS Potential; Q4 Earnings Miss
at Investor's Business Daily - Thu Feb 12, 9:45AM CST
Shares of Shire (SHPG) moved higher early Thursday as the Irish drugmaker's better-than-expected quarterly revenue and upbeat 2015 outlook offset an earnings miss. Reporting before the open, Shire logged fourth-quarter earnings of $2.63 per American...
AGN: 229.49 (+1.87), VRX: 167.00 (-0.50), SHPG: 239.82 (+6.11), SLXP: 152.35 (+3.17), NPSP: 45.88 (+0.03), ABBV: 58.05 (+1.00)
Acadia Pharmaceuticals Could Be The Most Sought After Company Of 2015
Investing Healthcare - at Seeking Alpha - Thu Feb 12, 8:40AM CST
ACAD: 34.21 (+0.37), AZN: 69.96 (+0.20), PDP: 42.52 (+0.28), ABBV: 58.05 (+1.00)
AbbVie Submits New Drug Application in Japan for its Investigational, All-Oral, Treatment for Chronic Hepatitis C
PR Newswire Europe - Wed Feb 11, 9:15PM CST
- Submission based on Phase 3 GIFT-I study in patients with genotype 1b chronic hepatitis C virus infection
ABBV: 58.05 (+1.00)
Axial Spondyloarthritis - Global Clinical Trials Review 2015
M2 - Wed Feb 11, 2:31PM CST
Research and Markets (http://www.researchandmarkets.com/research/lzmwwt/axial) has announced the addition of the "Axial Spondyloarthritis Global Clinical Trials Review, H1, 2015" report to their offering. This report provides elemental information and data relating to the clinical trials on Axial Spondyloarthritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Axial Spondyloarthritis. Scope: - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Pfizer Inc. - AbbVie Inc. - UCB Biosciences Inc. - Merck & Co., Inc. - UCB Biosciences GmbH Clinical Trial Overview of Top Institutes / Government - Glostrup University Hospital - Ghent University Hospital - Charite - Universitatsmedizin Berlin - Sociedad Espanola de Farmacologia Clinica - The First Affiliated Hospital of Zhengzhou University - Diakonhjemmet Hospital - Rheumatism Foundation Hospital - Tuen Mun Hospital - University hospital of North Norway - University of Zurich For more information visit http://www.researchandmarkets.com/research/lzmwwt/axial
PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00)
Comments On Gilead's Quarter And The Road Ahead
DoctoRx - at Seeking Alpha - Wed Feb 11, 11:57AM CST
JNJ: 99.62 (+1.18), PCYC: 163.28 (+0.23), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00)
6 Ways Rite Aid's Acquisition Of EnvisionRx Will Take Its Stock Higher
Brian Nichols - at Seeking Alpha - Wed Feb 11, 11:15AM CST
GILD: 101.90 (+1.10), CVS: 102.63 (-0.37), ABBV: 58.05 (+1.00), RAD: 8.34 (+0.25)
Biotech Stock Roundup: Achillion Impresses with HCV Data, Regeneron 4Q Results Top Estimates - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 11, 10:47AM CST
The hepatitis C virus (HCV) market remains in focus with Achillion (ACHN) presenting encouraging data.
GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), ABBV: 58.05 (+1.00), ALKS: 71.40 (-1.89), REGN: 402.40 (+0.66), XNPT: 6.69 (-0.21), CELG: 115.88 (+0.16)
Congratulations Covidien: You Escaped In Time
Chris DeMuth Jr. - Seeking Alpha - Wed Feb 11, 8:19AM CST
Originally published on February 4, 2015 The Shakedown In 2014, Obama vowed to punish tax inverting companies by any means necessary - inside and outside of legislation. He took scalps including Shire (NASDAQ: SHPG ) and Walgreens (NASDAQ: WBA...
VRX: 167.00 (-0.50), WBA: 78.73 (-1.23), MDT: 75.26 (+0.33), COV: 106.71 (-1.36), SHPG: 239.82 (+6.11), SLXP: 152.35 (+3.17), NPSP: 45.88 (+0.03), ABBV: 58.05 (+1.00)
Achillion: Hep C Drug Discounting May Hurt Our Market Value, Stock Price
at The Street - Wed Feb 11, 8:04AM CST
Achillion Pharmaceuticals announced a 10 million-share stock offering Tuesday night.
ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), CVS: 102.63 (-0.37), ABBV: 58.05 (+1.00)
